Protease Inhibitor Cocktail, mini-Tablet (EDTA-Free)
Cat# HY-K0011-50pcs
Size : 50pcs
Brand : MedChemExpress
Contact local distributor :
Phone : +1 850 650 7790
MCE Protease Inhibitor Cocktail, mini-Tablet (EDTA-Free) is a blend of 5 pan-protease inhibitors for protection of protein integrity.
or
Bulk Inquiry
* Please select Quantity before adding items.
- •Nat Biotechnol. 2024 Dec 3. [Abstract]
- •Signal Transduct Target Ther. 2023 Oct 23;8(1):404. [Abstract]
- •Signal Transduct Target Ther. 2021 Sep 4;6(1):333. [Abstract]
- •Cell Discov. 2021 Jun 22;7(1):46. [Abstract]
- •Cell Res. 2021 Mar;31(3):345-361. [Abstract]
- •Cell. 2020 Apr 30;181(3):621-636.e22. [Abstract]
- •Nat Metab. 2023 May 15. [Abstract]
- •Sci Immunol. 2022 Feb 4;7(68):eabk2092. [Abstract]
- •Cell Mol Immunol. 2021 Mar 11. [Abstract]
- •Chem Eng J. 2024 Oct 1.
- •Nat Commun. 2024 Oct 20;15(1):9050. [Abstract]
- •Cancer Commun (Lond). 2024 Oct 14. [Abstract]
- •J Clin Invest. 2024 Aug 15:e175023. [Abstract]
- •Mol Cell. 2024 May 29:S1097-2765(24)00434-9. [Abstract]
- •Adv Sci (Weinh). 2022 Oct 30;e2204697. [Abstract]
- •Adv Funct Mater. 2020, 2004886.
- •Autophagy. 2024 Dec;20(12):2719-2737. [Abstract]
- •Nucleic Acids Res. 2023 Mar 20;gkad197. [Abstract]
- •J Hazard Mater. 5 October 2022, 129689.
- •Cell Rep Med. 2022 Mar 15;3(3):100561. [Abstract]
- •Cell Rep Med. April 20, 2022.
- •Engineering. 14 August 2021.
- •Mol Ther. 2021 Jun 7;S1525-0016(21)00312-9. [Abstract]
- •Exp Hematol Oncol. 2021 Jun 4;10(1):35. [Abstract]
- •EMBO J. 2021 May 19;e106183. [Abstract]
- •Acta Pharm Sin B. 2021 Jun;11(6):1592-1606. [Abstract]
- •Sci Adv. 2021 Mar 3;7(10):eabe8591. [Abstract]
- •Theranostics. 2021 Mar 4;11(10):4825-4838. [Abstract]
- •Acta Pharm Sin B. 2020 Dec 15.
- •Theranostics. 2021 Jan 1;11(2):925-940. [Abstract]
- •EMBO Mol Med. 2020 Dec 7;e12798. [Abstract]
- •Theranostics. 2020 Oct 30;10(26):12223-12240. [Abstract]
- •J Exp Clin Cancer Res. 2020 Oct 21;39(1):222. [Abstract]
- •Theranostics. 2020 Jul 11;10(19):8834-8850. [Abstract]
- •Theranostics. 2020 Aug 2;10(21):9830-9842. [Abstract]
- •Environ Int. 2020 Aug;141:105755. [Abstract]
- •Cell Rep. 2024 Jun 27;43(7):114402. [Abstract]
- •Cell Rep. 2024 Apr 23;43(4):114018. [Abstract]
- •Hortic Res. 2024 Mar 6.
- •Cell Rep. 2023 Jun 22;42(7):112691. [Abstract]
- •Hortic Res. 2023 May 4.
- •Mater Design. 2023 May 16, 112007.
- •Pharmacol Res. 2023 Apr 15;106773. [Abstract]
- •Environ Pollut. 2022 Oct 17;120446. [Abstract]
- •Cell Rep. 2021 Nov 16;37(7):110025. [Abstract]
- •Cancer Lett. 20 October 2021.
- •Cell Death Dis. 2021 Jun 2;12(6):570. [Abstract]
- •J Colloid Interf Sci. 2021 May 24.
- •New Phytol. 2021 May 27. [Abstract]
- •Cell Prolif. 2021 May 5;e13045. [Abstract]
- •Cell Commun Signal. 2021 May 20;19(1):58. [Abstract]
- •Int J Biol Sci. 2021 Mar 21;17(5):1234-1249. [Abstract]
- •Cell Prolif. 2021 Apr 8;e13039. [Abstract]
- •Cell Death Dis. 2021 Mar 17;12(4):284. [Abstract]
- •ACS Appl Mater Interfaces. 2020 Oct 21;12(42):47330-47341. [Abstract]
- •Chemosphere. 2021 Jan;262:127891. [Abstract]
- •J Neuroinflammation. 2020 May 6;17(1):150. [Abstract]
- •Int J Biol Sci. 2021 Jan 1;17(1):339-352. [Abstract]
- •Cell Death Dis. 2020 May 11;11(5):351. [Abstract]
- •Cell Rep. 2019 Jun 18;27(12):3684-3695.e4. [Abstract]
- •J Mater Chem B. 2024 Jul 9. [Abstract]
- •Plant Physiol Biochem. 2024 May 30:212:108785. [Abstract]
- •J Med Chem. 2022 Aug 31. [Abstract]
- •JCI Insight. 2022 Feb 22;7(4):e149626. [Abstract]
- •J Transl Med. 2021 Sep 20;19(1):396. [Abstract]
- •J Invest Dermatol. 2021 Sep 14;S0022-202X(21)01672-9. [Abstract]
- •Cell Biosci. 2021 Jun 30;11(1):118. [Abstract]
- •Eur J Med Chem. 2021, 113605.
- •Biomater Sci. 2021 May 10. [Abstract]
- •Free Radic Biol Med. 2021 Jan 12;S0891-5849(20)32114-6. [Abstract]
- •Cell Death Discov. 2021 Jan 11;7(1):3. [Abstract]
- •Neural Regen Res. 2021 Jul;16(7):1308-1316. [Abstract]
- •Mol Ther-Nucl Acids. 2020 Oct 4;22:708-721. [Abstract]
- •PLoS Pathog. 2020 Oct 16;16(10):e1009002. [Abstract]
- •Phytomedicine. 2020, Jul 28.
- •Antioxidants. 2020 Aug 22;9(9):780. [Abstract]
- •Life Sci. 2020 Oct 15;259:118159. [Abstract]
- •Talanta. 2020 Nov 1;219:121281. [Abstract]
- •Biomed Pharmacother. 2020 Aug;128:110216. [Abstract]
- •Food Biosci. 2024 Oct.
- •iScience. 2023 Jul 27.
- •J Proteome Res. 2023 Jun 7. [Abstract]
- •J Biol Chem. 2023 Apr 17;104723. [Abstract]
- •J Cell Physiol. 2023 Feb 15. [Abstract]
- •Cells. 2022 Nov 14;11(22):3602. [Abstract]
- •Viruses. 2022, 14(11), 2349.
- •Int J Mol Sci. 2022 May 9;23(9):5259. [Abstract]
- •Cells. 2022 Feb 26;11(5):817. [Abstract]
- •iScience. 2022 Mar 1;25(4):104009. [Abstract]
- •Bioorg Chem. May 2022, 105714.
- •Viruses. 2022, 14(3), 514.
- •Cells. 2022, 11(3), 447.
- •Viruses. 2022 Feb 15;14(2):394. [Abstract]
- •Reprod Biol Endocrinol. 2022 Feb 2;20(1):25. [Abstract]
- •FASEB J. 2022 Feb;36(2):e22124. [Abstract]
- •Int Immunopharmacol. 2021 Dec 16;103:108430. [Abstract]
- •Int J Mol Sci. 2021 Aug 26;22(17):9245. [Abstract]
- •Neurochem Int. 2021, 105152.
- •Acs Biomater Sci Eng. 2021 Jun 30. [Abstract]
- •Front Pharmacol. 24 June 2021.
- •Front Cell Dev Biol. 2021 Jul 8;9:689727. [Abstract]
- •Commun Biol. 2021 Jun 23;4(1):777. [Abstract]
- •iScience. 2021, 102770.
- •Clin Epigenetics. 2021 Jun 10;13(1):127. [Abstract]
- •J Cell Physiol. 2021 May 27. [Abstract]
- •J Virol. 2021 May 19;JVI.00563-21. [Abstract]
- •Bioorg Chem. 2021 Aug;113:104981. [Abstract]
- •Int Immunopharmacol. 2021, 107785.
- •Front Pharmacol. 20 May 2021.
- •Commun Biol. 2021 Apr 22;4(1):491. [Abstract]
- •Biochem Pharmacol. 2021, 114542.
- •J Ethnopharmacol. 2021 Apr 20;114061. [Abstract]
- •Am J Cancer Res. 2021 Mar 1;11(3):930-944. [Abstract]
- •J Biol Chem. 2021, 100616.
- •J Biol Chem. Jan-Jun 2021;296:100614. [Abstract]
- •Oncol Rep. 2021 Apr 13.
- •Int Immunopharmacol. 2021, 107342.
- •Molecules. 2021, 26(6), 1580.
- •Cancer Sci. 2020 Nov;111(11):4142-4153. [Abstract]
- •J Biol Chem. 2021 Feb 2;100369. [Abstract]
- •Mol Cell Endocrinol. 2021 Feb 23;111218. [Abstract]
- •Cancer Sci. 2020 Nov;111(11):4102-4117. [Abstract]
- •Int J Mol Med. 2021 Jan;47(1):171-182. [Abstract]
- •J Mol Cell Cardiol. 2020 Dec;149:82-94. [Abstract]
- •Pharmaceutics. 2020 Oct 9;12(10):950. [Abstract]
- •Regen Ther. 2020 Oct 16;15:202-209. [Abstract]
- •Neurobiol Aging. 2021 Feb;98:10-20. [Abstract]
- •Am J Chin Med. 2020;48(6):1369-1383. [Abstract]
- •J Drug Deliv Sci Technol. 2020, 102048.
- •Viruses. 2020 Sep 2;12(9):974. [Abstract]
- •Sci Rep. 2020 Aug 3;10(1):13063. [Abstract]
- •Inflammation. 2020 Oct;43(5):1862-1875. [Abstract]
- •Zool Res. 2020 Sep 18;41(5):527-538. [Abstract]
- •Inflammation. 2020 Oct;43(5):1772-1779. [Abstract]
- •ACS Chem Neurosci. 2020 Jun 3;11(11):1682-1691. [Abstract]
- •Chem Commun (Camb). 2020 Jan 30;56(9):1389-1392. [Abstract]
- •Drug Des Devel Ther. 2020 May 18;14:1897-1908. [Abstract]
- •J Fungi (Basel). 2020 Jun 3;6(2):77. [Abstract]
- •Int J Mol Med. 2020 Aug;46(2):718-728. [Abstract]
- •Eur J Pharm Sci. 2020 Aug 1;151:105402. [Abstract]
- •J Drug Target. 2020 May 4:1-26. [Abstract]
- •Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):48. [Abstract]
- •Heliyon. 2024 May 24.
- •Front Biosci (Landmark Ed). 2024 Mar 15.
- •Biochim Biophys Acta Gen Subj. 2024 Mar 9:130595. [Abstract]
- •Brain Sci. 2023, 13(2), 262.
- •Neurotoxicology. 28 October 2022.
- •Placenta. 2022 Jan 10;118:55-65. [Abstract]
- •Mol Brain. 2022 Jan 3;15(1):4. [Abstract]
- •Insects. 2021, 12(9), 812.
- •Mol Med Rep. 2021 Aug;24(2):580. [Abstract]
- •Dig Dis Sci. 2022 Jun;67(6):2220-2231. [Abstract]
- •Cancer Med. 2021 May 7. [Abstract]
- •Mol Biol Rep. 2021 May 18. [Abstract]
- •J Orthop Surg Res. 2021 May 5;16(1):297. [Abstract]
- •J Cancer. 2021 Apr.
- •Biochem Biophys Res Commun. 2021 Apr 8;556:127-133. [Abstract]
- •Cancer Med. 2021 Apr;10(7):2470-2481. [Abstract]
- •BMC Complement Med Ther. 21, 88 (2021).
- •Theriogenology. 2021 Mar 19.
- •Breast Cancer. 2021 Jul;28(4):859-873. [Abstract]
- •Infect Immun. 2021 Feb 1;IAI.00696-20. [Abstract]
- •Biochem Biophys Res Commun. 2021 Feb 3;545:105-111. [Abstract]
- •Oncol Lett. 2021 Feb;21(2):117. [Abstract]
- •Infect Immun. 2020 Oct 19;88(11):e00537-20. [Abstract]
- •J Gen Virol. 2020 Nov;101(11):1145-1155. [Abstract]
- •Biochem Bioph Res Co. 2020 Sep 10;530(1):160-166. [Abstract]
- •Biochem Bioph Res Co. 2020 Jul 30;528(3):485-492. [Abstract]
- •Vet Microbiol. 2020 Jun;245:108707. [Abstract]
- •Vet Microbiol. 2020 Jun;245:108709. [Abstract]
- •Biochem Biophys Res Commun. 2020 Jul 12;528(1):105-111. [Abstract]
- •Toxicol In Vitro. 2020 Jun;65:104825. [Abstract]
- •Acta Neurobiol Exp. 2022, 82.
- •Xenobiotica. 2021 Aug 12;1-25. [Abstract]
- •Protein Expres Purif. 2021, 105860.
- •J Interv Card Electrophysiol. 2021 Feb 20. [Abstract]
- •J Gen Appl Microbiol. 2021 Apr 16;67(1):33-41. [Abstract]
- •Int J Med Mushrooms. 2020;22(10):979-990. [Abstract]
- •bioRxiv. 2024 September 19.
- •STAR Protoc. 2024 May 4;5(2):103054. [Abstract]
- •SSRN. 2024 Feb 6.
- •Research Square Preprint. 2023 Nov 9.
- •bioRxiv. 2023 Aug 15.
- •Research Square Preprint. 2023 Jun 21.
- •Research Square Preprint. 2022 May.
- •Research Square Preprint. 2022 May.
- •Research Square Preprint. 2022 Feb.
- •Leuk Res. December 2021, 106708.
- •Research Square Preprint. 2021 Aug.
- •Research Square Preprint. 2021 Aug.
- •Health Sci J. (2021): 1-7.
- •Research Square Preprint. 2021 Jun.
- •Methods Mol Biol. 2021;2348:231-242. [Abstract]
- •Research Square Preprint. 2021 May.
- •Bezmialem Science. 2021;9(2):164-70.
- •Biomed Res Int. 2021 Apr 16.
- •Research Square Preprint. 2021 Mar.
- •SSRN. 2021 Jan 26.
- •Research Square Preprint. 2020 Dec.
- •Research Square Preprint. 2020 Oct.
- •Research Square Preprint. 2020 Dec.
- •Mediat Inflamm. 2020 Oct 15;2020:4346367. [Abstract]
- •Preprints. 2020, 2020090120.
- •Research Square Preprint. 2020 Sep.
- •Evid Based Complement Alternat Med. 2020 Oct 30;2020:8894257. [Abstract]
- •bioRxiv. 2020 Jul.
WB
-
Protease Inhibitor Cocktail, mini-Tablet (EDTA-Free) purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 May 29:S1097-2765(24)00434-9. [Abstract]
- Expression of PABPC1 in H9 cells and FB neurons (A), H9 cells, and SH-SY5Y cells (B), revealed by western blotting. ACTIN was detected as control.
| Description & Advantages |
Endogenous proteins are produced and removed in a balanced state, so their cellular levels are generally stable under stable environmental conditions. However, protein degradation is enhanced when cells are studied in vitro. To prevent the degradation of proteins under such conditions, one can utilize a cocktail of small molecule inhibitors to block the action of proteases. MCE Protease Inhibitor Cocktail, mini-Tablet (EDTA-Free) is a blend of 5 pan-protease inhibitors for protection of protein integrity. This product can be applied in Western Blot analysis, IP, Co-IP, pull-down, IF, IHC, Kinase assay and etc. |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Storage |
4℃, 2 years |
|||||||||
| Components |
|
|||||||||
| Documentation |
Help & FAQs
-
Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
